AtriCureATRC -0.63%76 Days Payable is 79.81 as of Mar. 2026, which is 4% below its 10-year median of 83.36. GuruFocus rates ATRC with a GF Score™ of 76/100 and a GF Value™ of $39.73 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 795 Medical Devices & Instruments companies, AtriCure ranks better than 52.08% on this metric.
AtriCure's average Accounts Payable for the
three
months ended in Mar. 2026 was $27.9 Mil. AtriCure's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $31.9 Mil.
Hence, AtriCure's Days Payable for the
three
months ended in Mar. 2026 was 79.81.
The historical rank and industry rank for AtriCure's Days Payable or its related term are showing as below:
ATRC'
s Days Payable Range Over the Past 10 Years
Min: 68.69 Med: 83.36 Max: 97.11
Current: 71.64
During the past 13 years, AtriCure's highest Days Payable was 97.11. The lowest was 68.69. And the median was 83.36.
ATRC's Days Payable is ranked better than 52.08% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs ATRC: 71.64
AtriCure's Days Payable
increased
from Mar. 2025 (73.91) to Mar. 2026 (79.81).
It may suggest that AtriCuredelayed paying its suppliers.
AtriCure Days Payable Related Terms
AtriCure Days Payable Historical Data
* Premium members only.
The historical data trend for AtriCure's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, AtriCure's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AtriCure Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AtriCure's Days Payable distribution charts can be found below:
* The bar in red indicates where AtriCure's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
AtriCure's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AtriCure (ATRC) has a Days Payable of 79.81 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AtriCure and its competitors. This is near median its historical median of 83.36. Over the past decade, AtriCure's Days Payable has ranged from 68.69 to 97.11. According to the industry distribution chart, AtriCure ranks #381 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 47.9%.
Is AtriCure's Days Payable too high?
AtriCure's current Days Payable of 79.81 is near median its 10-year median of 83.36. Over the past 10 years, this metric has ranged from a low of 68.69 to a high of 97.11. The Medical Devices & Instruments industry median Days Payable is 67.87. AtriCure's value of 79.81 is 17.6% above this industry median. Based on the distribution chart, AtriCure ranks #381 out of 795 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, AtriCure has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AtriCure's Days Payable compare to STAA and NNNN?
According to the Medical Devices & Instruments industry distribution chart, AtriCure ranks #381 out of 795 companies for Days Payable. This puts AtriCure in the upper half of its industry. The industry median Days Payable is 67.87. AtriCure's value of 79.81 is 17.6% above this benchmark. Historically, AtriCure's own Days Payable has ranged from 68.69 to 97.11 over the past decade. While the company's 10-year median is 83.36 vs. the industry median of 67.87, AtriCure has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AtriCure's current Days Payable of 79.81 is 17.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on AtriCure and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AtriCure's current Days Payable is 79.81, which is near median its own 10-year median of 83.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AtriCure stock overvalued right now?
Based on GuruFocus' analysis, AtriCure (ATRC) is currently considered Modestly Undervalued. The stock's GF Value™ is $39.73, compared to a current price of $28.26 — trading 28.9% below its estimated fair value. The current Days Payable is 79.81, which is near median its 10-year median of 83.36 and 17.6% above the Medical Devices & Instruments industry median of 67.87. AtriCure's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For AtriCure (ATRC), the current Days Payable is 79.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AtriCure (ATRC) Overvalued in 2026?
Based on GuruFocus' analysis, AtriCure stock appears to be undervalued.
The current stock price of $28.26 is trading 28.9% below its estimated GF Value™ of $39.73.
GuruFocus considers AtriCure to be Modestly Undervalued.
Key valuation signals for ATRC:
Days Payable: 79.81 (near median its 10-year median of 83.36)
GF Value™: $39.73 vs. price of $28.26 (28.9% below fair value)
Industry Position: 17.6% above the Medical Devices & Instruments median (#381 of 795)
No single metric tells the full story. See the ATRC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
76GF Score
Get the complete analysis for ATRC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRC has been successfully added to your 
